v. United States, 757 F.2d 301, 308-09 (D.C.Cir.1985) (observing that “revenues and customers lost to competition which can be regained through competition are not irreparable”); see also Gulf Oil, 514 F.Supp. at 1026 (observing that the plaintiff must show that it will suffer harm that is “more than simply irretrievable”). Accordingly, the plaintiff has failed to demonstrate that the potential loss of sales and market share rises to the level of irreparable harm. The plaintiff’s concerns about the potential loss of goodwill and reputation are founded entirely on its belief that the approved generic tacrolimus may be more harmful than Prograf®, a belief that, as has already been discussed, lacks evidentiary support and is entirely speculative. See Bristol-Myers, 923 F.Supp. at 221 (<HOLDING>). For these reasons, the court concludes that
holding that a drug manufacturer failed to demonstrate irreparable harm because its claim that it will suffer a loss of sales should an anda be approved and drug product marketed before this case is disposed of on the merits is pure speculation as it had failed to provide any proof of economic loss and merely states that it would probably lose 20 to 30 percent of its market during the first year holding that the threat of irreparable harm must be immediate holding that the plaintiff had failed to produce sufficient evidence to establish constructive notice because the plaintiff did not present any evidence to establish that the oil was on the floor for any length of time holding that the plaintiff failed to establish irreparable harm because there is nothing before the court which would lead it to conclude that the competing drug will cause any harmful health effects holding that the district court erred when it failed to consider the presumption of irreparable harm